Shares of Editas Medicine (EDIT) are up 15% to $37.47 in early trading while Beam Therapeutics (BEAM) is up 13% to $24 per share after it was reported that rumors have circulated on Twitter regarding a possible tie-up of the companies. Representatives of Editas and Beam have declined to comment to Bloomberg on speculation on Twitter about a potential merger and The Fly has reached out to both companies for further comment.